{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:35:49Z","timestamp":1777178149041,"version":"3.51.4"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: De novo (pretreatment) EGFR T790M mutation is a rare molecular finding in non-small cell lung cancer (NSCLC) and has historically been associated with primary resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Evidence guiding optimal first-line management in this subgroup, particularly in elderly patients, remains limited. Case Presentation: We report a case of an elderly patient with treatment-na\u00efve advanced non-squamous NSCLC harboring a concurrent EGFR exon 19 deletion and de novo EGFR T790M mutation. Given the patient\u2019s age, significant cardiopulmonary comorbidities, and absence of rapidly progressive disease, a multidisciplinary tumor board recommended first-line osimertinib monotherapy. Treatment was well tolerated, with rapid improvement in performance status and no clinically significant adverse events. Serial contrast-enhanced CT restaging demonstrated RECIST 1.1\u2013defined stable disease, without development of new visceral, nodal, cerebral, or osseous metastases. The patient remains on continuous osimertinib therapy with durable disease control at the time of manuscript preparation. Conclusion: Primary EGFR T790M\u2013positive NSCLC can achieve durable disease control with first-line osimertinib, even in advanced age. While combination strategies with chemotherapy may improve survival outcomes in selected patients, treatment decisions in elderly individuals must carefully balance efficacy, toxicity, and quality of life. Chronological age alone should not discourage active targeted treatment when guided by molecular profiling and comprehensive clinical assessment.<\/jats:p>","DOI":"10.3390\/curroncol33050244","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:28:23Z","timestamp":1777040903000},"page":"244","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Case of Primary EGFR T790M Mutation in Treatment-Na\u00efve Advanced NSCLC: Clinical and Molecular Implications"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-9025","authenticated-orcid":false,"given":"George","family":"Dimitrov","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Medical University of Sofia, University Hospital \u201cTsaritsa Yoanna\u201d, 1527 Sofia, Bulgaria"},{"name":"Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery\u2014Leonardo da Vinci, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elitsa","family":"Kraevska","sequence":"additional","affiliation":[{"name":"Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery\u2014Leonardo da Vinci, 5800 Pleven, Bulgaria"},{"name":"Department of Pathoanatomy, Medical University of Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-5897","authenticated-orcid":false,"given":"Vladislav","family":"Nankov","sequence":"additional","affiliation":[{"name":"Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery\u2014Leonardo da Vinci, 5800 Pleven, Bulgaria"},{"name":"Department of Anatomy, Histology, Cytology and Biology, Medical University of Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Hlebarova","sequence":"additional","affiliation":[{"name":"Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery\u2014Leonardo da Vinci, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savelina","family":"Popovska","sequence":"additional","affiliation":[{"name":"Centre of Competence in Personalized Medicine, 3D and Telemedicine, Robotic Assisted and Minimally Invasive Surgery\u2014Leonardo da Vinci, 5800 Pleven, Bulgaria"},{"name":"Department of Pathoanatomy, Medical University of Pleven, 5800 Pleven, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stanzione, B., Del Conte, A., Bertoli, E., De Carlo, E., Bortolot, M., Torresan, S., Spina, M., and Bearz, A. (2025). Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies. Cancers, 17.","DOI":"10.3390\/cancers17091515"},{"key":"ref_4","first-page":"147","article-title":"EGFR T790M: Revealing the secrets of a gatekeeper","volume":"8","author":"Ko","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.02.006","article-title":"Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies","volume":"65","author":"Lim","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/ijc.32015","article-title":"Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation","volume":"144","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2018.03.005","article-title":"Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment","volume":"423","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/annonc\/mdt573","article-title":"Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing","volume":"25","author":"Yu","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2019.10.013","article-title":"Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first\/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project","volume":"140","author":"Pencreach","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2019.10.029","article-title":"Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors","volume":"139","author":"Matsumoto","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"50941","DOI":"10.18632\/oncotarget.16222","article-title":"The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR Mutation and Resistance of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"68123","DOI":"10.18632\/oncotarget.19243","article-title":"Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-na\u00efve patients with non-small cell lung cancer harboring EGFR mutations","volume":"8","author":"Tanaka","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Wu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S2213-2600(24)00124-3","article-title":"Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer","volume":"12","author":"Panagiotou","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1200\/JCO.23.01372","article-title":"Germline EGFR Mutations and Familial Lung Cancer","volume":"41","author":"Oxnard","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/JTO.0b013e3181913c9f","article-title":"EGFR T790M mutation: A double role in lung cancer cell survival?","volume":"4","author":"Suda","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fujiwara, T., Kobayashi, T., Yasuma, T., D\u2019Alessandro-Gabazza, C.N., Toda, M., Fujimoto, H., Fujiwara, K., Takeshita, A., Nishihama, K., and Okano, T. (2020). De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma. Cancers, 12.","DOI":"10.3390\/cancers12103074"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shao, H., and Wells, A. (2025). Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136157"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1200\/JCO.24.00762","article-title":"Therapy for Stage IV Non\u2013Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1","volume":"42","author":"Owen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJMoa2510308","article-title":"Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"394","author":"Planchard","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/1651-226X.2025.42602","article-title":"Quality of life in older patients with cancer and related unmet needs: A scoping review","volume":"64","author":"Springer","year":"2025","journal-title":"Acta Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107528","DOI":"10.1016\/j.lungcan.2024.107528","article-title":"Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment","volume":"190","author":"Pang","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_26","first-page":"100532","article-title":"Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20606","DOI":"10.1200\/JCO.2025.43.16_suppl.e20606","article-title":"Tumor proportion score (TPS) and response to first-line (1L) anti\u2013PD-1\/PD-L1 plus chemotherapy for metastatic non-small cell lung cancer (NSCLC): A real-world cohort study","volume":"43","author":"Faghmous","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-025-01927-1","article-title":"Immunotherapy in EGFR-mutant non-small cell lung cancer","volume":"26","author":"Wang","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/244\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:12:42Z","timestamp":1777176762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050244"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050244","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}